Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016;42(1):33-43.
doi: 10.1159/000442741. Epub 2016 Mar 31.

Anemia Management in the China Dialysis Outcomes and Practice Patterns Study

Li Zuo  1 , Mia Wang, Fanfan Hou, Yucheng Yan, Nan Chen, Jiaqi Qian, Mei Wang, Brian Bieber, Ronald L Pisoni, Bruce M Robinson, Shuchi Anand
Affiliations

Anemia Management in the China Dialysis Outcomes and Practice Patterns Study

Li Zuo et al. Blood Purif. 2016.

Abstract

Background: As the utilization of hemodialysis increases in China, it is critical to examine anemia management.

Methods: Using data from the China Dialysis Outcomes and Practice Patterns Study (DOPPS), we describe hemoglobin (Hgb) distribution and anemia-related therapies.

Results: Twenty one percent of China's DOPPS patients had Hgb <9 g/dl, compared with ≤10% in Japan and North America. A majority of medical directors targeted Hgb ≥11. Patients who were female, younger, or recently hospitalized had higher odds of Hgb <9; those with insurance coverage or on twice weekly dialysis had lower odds of Hgb <9. Iron use and erythropoietin-stimulating agents (ESAs) dose were modestly higher for patients with Hgb <9 compared with Hgb in the range 10-12.

Conclusion: A large proportion of hemodialysis patients in China's DOPPS do not meet the expressed Hgb targets. Less frequent hemodialysis, patient financial contribution, and lack of a substantial increase in ESA dose at lower Hgb concentrations may partially explain this gap. Video Journal Club 'Cappuccino with Claudio Ronco' at http://www.karger.com/?doi=442741.

PubMed Disclaimer

Conflict of interest statement

Disclosure Statement: The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Distribution of facility percentage of patients with Hgb <9 g/dl, by region.
Fig. 2
Fig. 2
a Median EPO dose, by Hgb category and region. b Percent of patients on IV iron, by Hgb category and region.
Fig. 3
Fig. 3
Distribution of patient Hgb, by frequency of measuring Hgb in China DOPPS facilities.
See this image and copyright information in PMC

References

    1. Ibrahim HN, Ishani A, Foley RN, Guo H, Liu J, Collins AJ. Temporal trends in red blood transfusion among US dialysis patients, 1992–2005. Am J Kidney Dis. 2008;52:1115–1121. - PubMed
    1. Levin NW, Lazarus JM, Nissenson AR. National Cooperative rHu Erythropoietin Study in patients with chronic renal failure – an interim report. The National Cooperative rHu Erythropoietin Study Group. Am J Kidney Dis. 1993;22(2 suppl 1):3–12. - PubMed
    1. Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE., Jr The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996;7:763–773. - PubMed
    1. United States Renal Database. USRDS Atlas: Costs of ESRD. 2012
    1. Baboolal K, McEwan P, Sondhi S, Spiewanowski P, Wechowski J, Wilson K. The cost of renal dialysis in a UK setting – a multicentre study. Nephrol Dial Transplant. 2008;23:1982–1989. - PubMed